WO2007071448A3 - Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation - Google Patents
Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation Download PDFInfo
- Publication number
- WO2007071448A3 WO2007071448A3 PCT/EP2006/012501 EP2006012501W WO2007071448A3 WO 2007071448 A3 WO2007071448 A3 WO 2007071448A3 EP 2006012501 W EP2006012501 W EP 2006012501W WO 2007071448 A3 WO2007071448 A3 WO 2007071448A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inducers
- inhibitors
- muscle relaxation
- synthetic peptides
- neurotransmitter secretion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/158,775 US8318898B2 (en) | 2005-12-23 | 2006-12-22 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation |
MX2008008233A MX2008008233A (en) | 2005-12-23 | 2006-12-22 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation. |
EP06847000A EP1976869A2 (en) | 2005-12-23 | 2006-12-22 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation |
CA002634824A CA2634824A1 (en) | 2005-12-23 | 2006-12-22 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation |
BRPI0620414-7A BRPI0620414A2 (en) | 2005-12-23 | 2006-12-22 | Synthetic Peptides for Use as Neurotransmitter Secretion Inhibitors and as Cellular Relaxation Inducers |
US13/685,114 US20130323187A1 (en) | 2005-12-23 | 2012-11-26 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75360705P | 2005-12-23 | 2005-12-23 | |
US60/753,607 | 2005-12-23 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/685,114 Continuation US20130323187A1 (en) | 2005-12-23 | 2012-11-26 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007071448A2 WO2007071448A2 (en) | 2007-06-28 |
WO2007071448A3 true WO2007071448A3 (en) | 2007-11-22 |
Family
ID=38123675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/012501 WO2007071448A2 (en) | 2005-12-23 | 2006-12-22 | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation |
Country Status (9)
Country | Link |
---|---|
US (2) | US8318898B2 (en) |
EP (2) | EP1976869A2 (en) |
CN (2) | CN101374860A (en) |
BR (1) | BRPI0620414A2 (en) |
CA (1) | CA2634824A1 (en) |
MX (1) | MX2008008233A (en) |
SG (1) | SG163525A1 (en) |
TW (1) | TWI392517B (en) |
WO (1) | WO2007071448A2 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
AU2007353340A1 (en) * | 2006-12-01 | 2008-11-20 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
WO2008082885A2 (en) * | 2006-12-29 | 2008-07-10 | Revance Therapeutics, Inc. | Transport molecules using reverse sequence hiv-tat polypeptides |
JP2008284318A (en) * | 2007-05-15 | 2008-11-27 | Kosumedei Seiyaku Kk | Microneedle for dosing, including living body origin matter |
ES2356883B1 (en) * | 2008-07-24 | 2012-02-22 | Bcn Peptides, S.A. | COMPOSITION FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION. |
EP2560629B1 (en) | 2010-04-23 | 2020-06-03 | Massachusetts Eye & Ear Infirmary | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells |
US20140024598A1 (en) | 2010-11-01 | 2014-01-23 | Demetrios Vavvas | Methods and compositions for preserving retinal ganglion cells |
DK2714718T3 (en) * | 2011-05-24 | 2017-04-24 | Symic Ip Llc | Hyaluronic acid-binding synthetic peptidoglycans, preparation and methods of use |
WO2013059791A2 (en) | 2011-10-21 | 2013-04-25 | Massachusetts Eye And Ear Infirmary | Methods and compositions for promoting axon regeneration and nerve function |
EP2802337B2 (en) * | 2011-11-07 | 2021-01-20 | Feng Tian | Peptide-based compounds as inhibitors of neurotransmitter secretion |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10149812B2 (en) | 2012-04-13 | 2018-12-11 | Activen | Cosmetic composition comprising a muconopeptide |
CN104334155B (en) * | 2012-04-13 | 2017-06-16 | 艾克迪文 | Cosmetic composition comprising μ cone shell peptides |
WO2013156064A1 (en) * | 2012-04-17 | 2013-10-24 | Activen | Anti-wrinkles cosmetic composition comprising a mu-conopeptide |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
JP2016535770A (en) | 2013-11-01 | 2016-11-17 | スフェリウム バイオメッド エス.エル. | Inclusion body for transdermal delivery of therapeutic and cosmetic substances |
WO2015164822A1 (en) | 2014-04-25 | 2015-10-29 | Purdue Research Foundation | Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction |
KR20170005819A (en) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | Natural combination hormone replacement formulations and therapies |
JP2017523138A (en) | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | Transdermal cream |
WO2016149637A1 (en) * | 2015-03-19 | 2016-09-22 | Kansas State University Research Foundation | Nanoplatforms for arginase, indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase detection by posttranslational modification |
US20180177722A1 (en) | 2015-06-26 | 2018-06-28 | Stc.Unm | Coenzyme Q10 Aerosol |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
CN106546673A (en) * | 2016-10-20 | 2017-03-29 | 吉尔生化(上海)有限公司 | A kind of method that utilization high performance liquid chromatography separates palmityl Wushengtai 3 |
WO2019004758A2 (en) * | 2017-06-28 | 2019-01-03 | 주식회사 엘지생활건강 | Cosmetic composition containing fusion protein with skin penetration enhancing peptide conjugated thereto for skin improvement |
CN110809478A (en) | 2017-07-07 | 2020-02-18 | 斯米克Ip有限公司 | Synthetic bioconjugates |
CN107469065B (en) * | 2017-07-19 | 2021-05-18 | 广州医科大学 | Application of snake venom-like three-peptide in preparation of medicine for treating skin ulcer |
WO2020060202A1 (en) * | 2018-09-18 | 2020-03-26 | 한국생산기술연구원 | Expression cassette for preparing thymulin or argireline, and use thereof |
KR102124036B1 (en) * | 2018-09-18 | 2020-06-19 | 한국생산기술연구원 | A expression cassette for preparation of argireline and use thereof |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
CN111620928B (en) * | 2020-06-01 | 2023-02-28 | 陕西慧康生物科技有限责任公司 | Large-scale synthesis method of hexapeptide |
US20230218498A1 (en) * | 2020-06-12 | 2023-07-13 | Caregen Co, Ltd. | Composition comprising pentapeptide as active ingredient |
KR102584000B1 (en) | 2021-01-19 | 2023-10-06 | 김기연 | Sport lotion composition comprising neurotransmitter regulating peptide |
CN114835780B (en) * | 2022-06-29 | 2022-09-27 | 中国农业大学 | Oligopeptide MEDEI separated from chilli seeds and application thereof in preventing or treating cancers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034620A1 (en) * | 1996-03-18 | 1997-09-25 | The Regents Of The University Of California | Peptide inhibitors of neurotransmitter secretion by neuronal cells |
EP1180524A1 (en) * | 1999-04-23 | 2002-02-20 | Lipotec, S.A. | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides |
US20050281816A1 (en) * | 2002-10-11 | 2005-12-22 | Norbert Lamping | Modular antigen transporter molecules (MAT molecules) for modulating immune reactions, associated constructs, methods and uses |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (en) * | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) * | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4277437A (en) * | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
DE69332197T2 (en) | 1992-03-13 | 2003-04-17 | Organon Teknika Bv | Epstein-Barr virus related peptides and nucleic acid segments |
CA2227786A1 (en) | 1995-07-28 | 1997-02-13 | Marie Curie Cancer Care | Transport proteins and their uses |
JPH10298196A (en) | 1997-04-28 | 1998-11-10 | Nippon Fine Chem Co Ltd | Cosmetic |
US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
WO1999055899A1 (en) * | 1998-04-28 | 1999-11-04 | Washington University | Methods for transducing fusion molecules |
MXPA01002149A (en) * | 1998-09-01 | 2003-03-27 | Idea Ag | Electrically controlled transport of charged penetrants across barriers. |
FR2783169B1 (en) * | 1998-09-15 | 2001-11-02 | Sederma Sa | COSMETIC OR DERMOPHARMACEUTICAL USE OF PEPTIDES FOR HEALING AND FOR IMPROVING THE SKIN APPEARANCE DURING NATURAL OR ACCELERATED AGING (HELIODERMIA, POLLUTION) |
FR2784028B1 (en) | 1998-10-01 | 2003-02-07 | Oreal | USE OF A PEPTIDE FOR PREVENTING SKIN INTOLERANCE REACTIONS, ESPECIALLY IN COSMETIC COMPOSITIONS |
US6942981B1 (en) * | 1999-05-14 | 2005-09-13 | Arbor Vita Corporation | Method of determining interactions with PDZ-domain polypeptides |
EP1178817A2 (en) * | 1999-05-14 | 2002-02-13 | Arbor Vita Corporation | Molecular interactions in haematopoietic cells |
US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
US6794362B1 (en) | 2000-05-30 | 2004-09-21 | Connective Tissue Imagineering Llc | Asparagine containing elastin peptide analogs |
ATE391791T1 (en) | 2000-08-25 | 2008-04-15 | Aventis Pharma Inc | MEMBRANE-PENETRATING PEPTIDES AND APPLICATIONS THEREOF |
DE10051120A1 (en) * | 2000-10-14 | 2002-04-25 | Raymond A & Cie | Device for retaining and/or fixing of flat objects, especially ribbon cable for motor vehicle bodywork parts, includes base plate from which extend two elastically splayed extensions, the ends of which are joined via a three-part web |
AU2002224079B2 (en) | 2000-11-22 | 2006-11-16 | Otsuka Pharmaceutical Co., Ltd. | O/W emulsion composition and method of preparing the same |
EP1487870A2 (en) | 2002-01-09 | 2004-12-22 | Université de Lausanne | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
US6821524B2 (en) | 2002-06-03 | 2004-11-23 | Jan Marini Skin Research, Inc. | Cosmetic skin care compositions |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US20070166281A1 (en) * | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
JP5137814B2 (en) * | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | Conjugation of PEG and polysialicosomal enzymes via acid labile linkers for therapeutic targeting |
-
2006
- 2006-12-22 EP EP06847000A patent/EP1976869A2/en not_active Withdrawn
- 2006-12-22 BR BRPI0620414-7A patent/BRPI0620414A2/en not_active IP Right Cessation
- 2006-12-22 CN CNA2006800529964A patent/CN101374860A/en active Pending
- 2006-12-22 CN CN2011103621448A patent/CN102408470A/en active Pending
- 2006-12-22 EP EP09175443A patent/EP2172210A1/en not_active Withdrawn
- 2006-12-22 WO PCT/EP2006/012501 patent/WO2007071448A2/en active Application Filing
- 2006-12-22 US US12/158,775 patent/US8318898B2/en not_active Expired - Fee Related
- 2006-12-22 CA CA002634824A patent/CA2634824A1/en not_active Abandoned
- 2006-12-22 SG SG201004587-0A patent/SG163525A1/en unknown
- 2006-12-22 MX MX2008008233A patent/MX2008008233A/en active IP Right Grant
- 2006-12-25 TW TW095148861A patent/TWI392517B/en not_active IP Right Cessation
-
2012
- 2012-11-26 US US13/685,114 patent/US20130323187A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034620A1 (en) * | 1996-03-18 | 1997-09-25 | The Regents Of The University Of California | Peptide inhibitors of neurotransmitter secretion by neuronal cells |
EP1180524A1 (en) * | 1999-04-23 | 2002-02-20 | Lipotec, S.A. | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides |
US20050281816A1 (en) * | 2002-10-11 | 2005-12-22 | Norbert Lamping | Modular antigen transporter molecules (MAT molecules) for modulating immune reactions, associated constructs, methods and uses |
Non-Patent Citations (2)
Title |
---|
DIETZ G P H ET AL: "Delivery of bioactive molecules into the cell: the Trojan horse approach", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 27, no. 2, 1 October 2004 (2004-10-01), pages 85 - 131, XP004599335, ISSN: 1044-7431 * |
LUPO MARY P: "Cosmeceutical peptides.", DERMATOLOGIC SURGERY : OFFICIAL PUBLICATION FOR AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY [ET AL.] JUL 2005, vol. 31, no. 7 Pt 2, July 2005 (2005-07-01), pages 832 - 836 ; dis, XP002438372, ISSN: 1076-0512 * |
Also Published As
Publication number | Publication date |
---|---|
EP1976869A2 (en) | 2008-10-08 |
EP2172210A1 (en) | 2010-04-07 |
CA2634824A1 (en) | 2007-06-28 |
CN101374860A (en) | 2009-02-25 |
CN102408470A (en) | 2012-04-11 |
US20090226387A1 (en) | 2009-09-10 |
US20130323187A1 (en) | 2013-12-05 |
WO2007071448A2 (en) | 2007-06-28 |
US8318898B2 (en) | 2012-11-27 |
TW200731997A (en) | 2007-09-01 |
TWI392517B (en) | 2013-04-11 |
SG163525A1 (en) | 2010-08-30 |
MX2008008233A (en) | 2009-03-27 |
BRPI0620414A2 (en) | 2014-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007071448A3 (en) | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation | |
MX2009008104A (en) | Hepcidin, hepcidin antagonists and methods of use. | |
HK1123294A1 (en) | Pyrazolopyrimidine derivatives for use as kinase antagonists | |
EP2200436A4 (en) | Substituted pyrimidinyl-amines as protein kinase inhibitors | |
HK1129890A1 (en) | C-met protein kinase inhibitors for the treatment of proliferative disorders | |
WO2011047087A3 (en) | Protein detection via nanoreporters | |
BRPI0813216A2 (en) | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEM. | |
UA101478C2 (en) | Compounds useful as inhibitors of raf protein kinase | |
IL198487A0 (en) | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | |
PL2193133T3 (en) | Imidazolothiadiazoles for use as protein kinase inhibitors | |
ZA201004243B (en) | Benzofuropyrimidinones as protein kinase inhibitors | |
PL1874770T3 (en) | Phenylacetamides suitable as protein kinase inhibitors | |
MX339584B (en) | Pi3 kinase inhibitors and uses thereof. | |
IL198398A0 (en) | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | |
MX2010004219A (en) | Cd19 binding agents and uses thereof. | |
DE602008006293D1 (en) | System for reducing the wear of joint surface implants | |
SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
WO2008144522A8 (en) | Tissue securing and sealing apparatus and related methods of use | |
WO2008121767A3 (en) | Stitched polypeptides | |
EP2076128A4 (en) | Protein kinase inhibitors and methods for using thereof | |
WO2007073497A3 (en) | Calcium channel antagonists | |
BRPI0816784A2 (en) | Neuroendocrine factors for the treatment of degenerative diseases | |
ATE521365T1 (en) | KININ ANTAGONISTS FOR THE TREATMENT OF BLADDER DISORDER | |
EP2133342A4 (en) | Protein tyrosine phosphatase 1b inhibitor, preparation methods and uses thereof | |
WO2007075852A3 (en) | Calcium channel antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2634824 Country of ref document: CA Ref document number: MX/A/2008/008233 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3845/CHENP/2008 Country of ref document: IN Ref document number: 2006847000 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680052996.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12158775 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0620414 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080623 |